,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The approximate aggregate market value of voting and non voting stock held by non affiliates of the registrant was $138,056,968,288 as of June 30, 2020.(A)","138,056,968,288",['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,amgn,"The approximate aggregate market value of voting and non voting stock held by non affiliates of the registrant was $138,056,968,288 as of June 30, 2020.","$138,056,968,288",MONEY,"The approximate aggregate market value of voting and non voting stock held by non affiliates of the registrant was $138,056,968,288 as of June 30, 2020.","['approximate aggregate market value of non voting', 'non affiliates of registrant', 'approximate aggregate market value', 'non voting', 'non affiliates']","['approximate aggregate market value of non voting', 0.9800207018852234, 'what is approximate aggregate market value of non voting ?', '$138,056,968,288']",approximate aggregate market value of non voting,0.9800207018852234,what is approximate aggregate market value of non voting ?,"$138,056,968,288",Approximate aggregate market value
1,"Common stock and additional paid in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding— 578.3 shares in 2020 and 591.4 shares in 2019",578.3,"['Common Stock, Shares, Outstanding', 'Common stock and additional paid in capital, shares outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,amgn,"Common stock and additional paid in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding— 578.3 shares in 2020 and 591.4 shares in 2019",578.3,CARDINAL,"Common stock and additional paid in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding— 578.3 shares in 2020 and 591.4 shares in 2019","['par value per share', 'shares', 'shares']","['outstanding', 0.9761515855789185, 'What is 578.3 ?', 'outstanding']",outstanding,0.9761515855789183,What is 578.3 ?,outstanding, shares in 2020
2,"Common stock and additional paid in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding— 578.3 shares in 2020 and 591.4 shares in 2019",591.4,"['Common Stock, Shares, Outstanding', 'Common stock and additional paid in capital, shares outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,amgn,"Common stock and additional paid in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding— 578.3 shares in 2020 and 591.4 shares in 2019",591.4,CARDINAL,"Common stock and additional paid in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding— 578.3 shares in 2020 and 591.4 shares in 2019","['par value per share', 'shares', 'shares']","['', 0, '', '']",,0.0,,,Outstanding shares in 2019
3,"Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.",30,['Revenue payment term'],amgn_RevenuePaymentArrangementTerm,durationItemType,amgn,"Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.",30 to 120 days,DATE,"Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.","['date of shipment', 'shipment of performance obligation', 'Payment terms', 'performance obligation']","['date of shipment', 0.862267792224884, 'what is date of shipment ?', '30 to 120 days']",date of shipment,0.862267792224884,what is date of shipment ?,30 to 120 days,Payment terms
4,"Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.",120,['Revenue payment term'],amgn_RevenuePaymentArrangementTerm,durationItemType,amgn,"Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.",30 to 120 days,DATE,"Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.","['date of shipment', 'shipment of performance obligation', 'Payment terms', 'performance obligation']","['date of shipment', 0.862267792224884, 'what is date of shipment ?', '30 to 120 days']",date of shipment,0.862267792224884,what is date of shipment ?,30 to 120 days,Payment terms
5,"SG&A costs are primarily composed of salaries, benefits and other staff related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.",962,['Advertising cost'],us-gaap_AdvertisingExpense,monetaryItemType,amgn,"Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively.",$962 million,MONEY,"Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively.",['Advertising costs'],"['Advertising costs', 0.5417976975440979, 'what is Advertising costs ?', '$962 million']",Advertising costs,0.5417976975440979,what is Advertising costs ?,$962 million,"Advertising costs during the year ended December 31, 2020"
6,"SG&A costs are primarily composed of salaries, benefits and other staff related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.",789,['Advertising cost'],us-gaap_AdvertisingExpense,monetaryItemType,amgn,"Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively.",$789 million,MONEY,"Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively.",['Advertising costs'],"['', 0, '', '']",,0.0,,,Advertising costs
7,"SG&A costs are primarily composed of salaries, benefits and other staff related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.",674,['Advertising cost'],us-gaap_AdvertisingExpense,monetaryItemType,amgn,"Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively.",$674 million,MONEY,"Advertising costs are expensed as incurred and were $962 million, $789 million and $674 million during the years ended December 31, 2020, 2019 and 2018, respectively.",['Advertising costs'],"['', 0, '', '']",,0.0,,,"Advertising costs during the year ended December 31, 2018"
8,"Adoption of the new standard resulted in total lease liabilities of $510 million and right of use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is primarily related to previously existing lease liabilities. The standard did not materially impact our Consolidated Statements of Income and had no impact on our Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 13, Leases.",510,"['Present value of lease liabilities', 'Total lease liabilities']",us-gaap_OperatingLeaseLiability,monetaryItemType,amgn,"Adoption of the new standard resulted in total lease liabilities of $510 million and right of use (ROU) assets of $439 million as of January 1, 2019.",$510 million,MONEY,"Adoption of the new standard resulted in total lease liabilities of $510 million and right of use  assets of $439 million as of January 1, 2019.","['Adoption of new standard', 'total lease liabilities', 'right of use assets', 'use assets', 'new standard', 'total lease liabilities', 'use assets']","['total lease liabilities', 0.9801393151283264, 'what is total lease liabilities ?', '$510 million']",total lease liabilities,0.9801393151283264,what is total lease liabilities ?,$510 million,Total lease liabilities
9,"Adoption of the new standard resulted in total lease liabilities of $510 million and right of use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is primarily related to previously existing lease liabilities. The standard did not materially impact our Consolidated Statements of Income and had no impact on our Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 13, Leases.",439,"['Operating lease, Right of use asset', 'Other assets']",us-gaap_OperatingLeaseRightOfUseAsset,monetaryItemType,amgn,"Adoption of the new standard resulted in total lease liabilities of $510 million and right of use (ROU) assets of $439 million as of January 1, 2019.",$439 million,MONEY,"Adoption of the new standard resulted in total lease liabilities of $510 million and right of use  assets of $439 million as of January 1, 2019.","['Adoption of new standard', 'total lease liabilities', 'right of use assets', 'use assets', 'new standard', 'total lease liabilities', 'use assets']","['right of use assets', 0.9773898720741272, 'what is right of use assets ?', '$439 million']",right of use assets,0.9773898720741272,what is right of use assets ?,$439 million,right of use assets
10,"On November 21, 2019, we acquired worldwide rights to Otezla®, the only oral, non biologic treatment for psoriasis and psoriatic arthritis, along with certain related assets and liabilities, from Celgene Corporation (Celgene). Otezla® is primarily used for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than 50 markets outside the United States, including the European Union and Japan. The acquisition was accounted for as an asset acquisition under GAAP because substantially all of the value of the assets acquired was concentrated in the global intellectual property rights of Otezla®. The operations of Otezla® have been included in our consolidated financial statements commencing on the acquisition date.",50,['Approved markets'],amgn_ApprovedMarkets,integerItemType,amgn,"Otezla® is primarily used for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than 50 markets outside the United States, including the European Union and Japan.",more than 50,CARDINAL,"Otezla® is primarily used for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than 50 markets outside the United States, including the European Union and Japan.","['treatment of patients', 'treatment with severe plaque psoriasis', 'markets outside United States', 'Otezla ®', 'severe plaque psoriasis']","['Otezla ®', 0.6497681736946106, 'how many Otezla ® ?', 'more than 50']",Otezla ®,0.6497681736946106,how many Otezla ® ?,more than 50,markets outside the United States
11,"The developed product technology rights acquired relate to Otezla®. The estimated fair value was determined by using a multi period excess earnings income approach, which is based on the present value of the incremental after tax cash flows attributable only to the intangible asset. The developed product technology rights will be amortized over a weighted average period of 8.5 years by using the straight line method.",8.5,['Weighted average period of amortization'],us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife,durationItemType,amgn,The developed product technology rights will be amortized over a weighted average period of 8.5 years by using the straight line method.,8.5 years,DATE,The developed product technology rights will be amortized over a weighted average period of 8.5 years by using the straight line method.,"['weighted average period of years', 'technology rights', 'weighted average period', 'straight line method']","['weighted average period', 0.9826269745826721, 'what is weighted average period ?', '8.5 years']",weighted average period,0.982626974582672,what is weighted average period ?,8.5 years,weighted average period
12,"The estimated fair value of marketing related rights, which relate to assembled workforce, was determined using a replacement cost approach, which consists of developing an estimate of the current cost of a similar new asset having the nearest equivalent utility to the asset being valued. The assembled workforce will be amortized over a period of 5 years by using the straight line method.",5,['Weighted average period of amortization'],us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife,durationItemType,amgn,The assembled workforce will be amortized over a period of 5 years by using the straight line method.,5 years,DATE,The assembled workforce will be amortized over a period of 5 years by using the straight line method.,"['period of years', 'assembled workforce', 'straight line method']","['The assembled workforce', 0.39727506041526794, 'What is 5 years ?', 'The assembled workforce']",The assembled workforce,0.3972750604152679,What is 5 years ?,The assembled workforce,The assembled workforce will be amortized over a period of 5 years by using the straight line method.
13,"The estimated fair value of the acquired inventory was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer's effort are applied. Inventory fair value adjustments will be amortized as inventory turns over, which we estimate to approximate 2.5 years.",2.5,"['Acquired assets, weighted useful life']",amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife,durationItemType,amgn,"Inventory fair value adjustments will be amortized as inventory turns over, which we estimate to approximate 2.5 years.",2.5 years,DATE,"Inventory fair value adjustments will be amortized as inventory turns over, which we estimate to approximate 2.5 years.",['fair value adjustments'],"['Inventory fair value adjustments', 0.6110112071037292, 'What is 2.5 years ?', 'Inventory fair value adjustments']",Inventory fair value adjustments,0.6110112071037292,What is 2.5 years ?,Inventory fair value adjustments,Inventory fair value adjustments
14,"Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million. The tax effects of the acquisition are based on Amgen's estimated blended statutory tax rate of 20%.",119,['Adjustments to carrying value of intangible assets'],us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles,monetaryItemType,amgn,"Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million.",$119 million,MONEY,"Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million.","['Use of methodology', 'increase to carrying value', 'carrying value of intangible assets', 'intangible assets', 'net deferred tax liability', 'deferred credit', 'intangible assets']","['carrying value of intangible assets', 0.9341468811035156, 'what is carrying value of intangible assets ?', '$119 million']",carrying value of intangible assets,0.9341468811035156,what is carrying value of intangible assets ?,$119 million,"Carrying value of intangible assets

Entity:
$24 million
Phrase:
Net deferred tax liability

Entity:
$96 million
Phrase:
Deferred credit"
15,"Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million. The tax effects of the acquisition are based on Amgen's estimated blended statutory tax rate of 20%.",24,['Adjustments to deferred tax liability'],amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities,monetaryItemType,amgn,"Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million.",$24 million,MONEY,"Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million.","['Use of methodology', 'increase to carrying value', 'carrying value of intangible assets', 'intangible assets', 'net deferred tax liability', 'deferred credit', 'intangible assets']","['net deferred tax liability', 0.9838773012161255, 'what is net deferred tax liability ?', '$24 million']",net deferred tax liability,0.9838773012161256,what is net deferred tax liability ?,$24 million,Deferred Tax Liability
16,"Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million. The tax effects of the acquisition are based on Amgen's estimated blended statutory tax rate of 20%.",96,['Adjustments to deferred credit'],amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits,monetaryItemType,amgn,"Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million.",$96 million,MONEY,"Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million.","['Use of methodology', 'increase to carrying value', 'carrying value of intangible assets', 'intangible assets', 'net deferred tax liability', 'deferred credit', 'intangible assets']","['deferred credit', 0.9698005318641663, 'what is deferred credit ?', '$96 million']",deferred credit,0.9698005318641664,what is deferred credit ?,$96 million,deferred credit
17,"Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119 million, a net deferred tax liability of $24 million and a deferred credit of $96 million. The tax effects of the acquisition are based on Amgen's estimated blended statutory tax rate of 20%.",20,['Estimated blended statutory rate'],amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate,percentItemType,amgn,The tax effects of the acquisition are based on Amgen’s estimated blended statutory tax rate of 20%.,20%,PERCENT,The tax effects of the acquisition are based on Amgen’s estimated blended statutory tax rate of 20%.,"['tax effects of acquisition', 'estimated blended statutory tax rate of %', 'tax effects', 'blended statutory tax rate']","['blended statutory tax rate', 0.9811335802078247, 'what is blended statutory tax rate ?', '20%']",blended statutory tax rate,0.9811335802078248,what is blended statutory tax rate ?,20%,Amgen's estimated blended statutory tax rate
18,"On July 15, 2019, we acquired all of the outstanding stock of Nuevolution AB (Nuevolution), a publicly traded, Denmark based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $183 million in cash. The transaction, which was accounted for as a business combination, expands our ability to discover novel small molecules against difficult to drug targets and with greater speed and efficiency. Nuevolution's operations, which are not material, have been included in our consolidated financial statements commencing on the acquisition date.",183,"['Consideration transferred', 'Total consideration transferred to acquire K A']",us-gaap_BusinessCombinationConsiderationTransferred1,monetaryItemType,amgn,"On July 15, 2019, we acquired all of the outstanding stock of Nuevolution AB (Nuevolution), a publicly traded, Denmark based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $183 million in cash.",$183 million,MONEY,"On July 15, 2019, we acquired all of the outstanding stock of Nuevolution AB , a publicly traded, Denmark based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $183 million in cash.","['outstanding stock of Nuevolution AB', 'traded based biotechnology company with leading small discovery platform', 'traded based biotechnology company for total consideration', 'total consideration', 'outstanding stock', 'biotechnology company', 'small discovery platform', 'total consideration']","['total consideration', 0.814585268497467, 'what is total consideration ?', '$183 million in cash']",total consideration,0.814585268497467,what is total consideration ?,$183 million in cash,Outstanding stock of Nuevolution AB
19,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.",150,['Finite lived Intangible Assets Acquired'],us-gaap_FinitelivedIntangibleAssetsAcquired1,monetaryItemType,amgn,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.",$150 million,MONEY,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.","['intangible assets', 'technology rights for discovery platform', 'estimated useful life of years', 'goodwill', 'deferred tax liabilities', 'other net assets', 'intangible assets', 'technology rights', 'discovery platform', 'useful life']","['technology rights for a drug discovery platform', 0.2907242476940155, 'What is $150 million ?', 'technology rights for a drug discovery platform']",technology rights for a drug discovery platform,0.2907242476940155,What is $150 million ?,technology rights for a drug discovery platform,"Nuevolution technology rights

Entity: 
$26 million
Phrase: 
Nuevolution goodwill

Entity: 
$22 million
Phrase: 
Nuevolution deferred tax liabilities

Entity: 
$29 million
Phrase: 
Nuevolution other net assets"
20,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.",10,['Weighted average period of amortization'],us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife,durationItemType,amgn,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.",10 years,DATE,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.","['intangible assets', 'technology rights for discovery platform', 'estimated useful life of years', 'goodwill', 'deferred tax liabilities', 'other net assets', 'intangible assets', 'technology rights', 'discovery platform', 'useful life']","['useful life', 0.8553416728973389, 'what is useful life ?', '10 years']",useful life,0.8553416728973389,what is useful life ?,10 years,Useful life of technology rights
21,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.",26,"['Goodwill', 'Goodwill']",us-gaap_Goodwill,monetaryItemType,amgn,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.",$26 million,MONEY,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.","['intangible assets', 'technology rights for discovery platform', 'estimated useful life of years', 'goodwill', 'deferred tax liabilities', 'other net assets', 'intangible assets', 'technology rights', 'discovery platform', 'useful life']","['goodwill', 0.639507532119751, 'What is $26 million ?', 'goodwill']",goodwill,0.639507532119751,What is $26 million ?,goodwill,Nuevolution acquisition goodwill
22,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.",22,"['Fair value of liabilities assumed, deferred tax liabilities']",us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities,monetaryItemType,amgn,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.",$22 million,MONEY,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.","['intangible assets', 'technology rights for discovery platform', 'estimated useful life of years', 'goodwill', 'deferred tax liabilities', 'other net assets', 'intangible assets', 'technology rights', 'discovery platform', 'useful life']","['deferred tax liabilities', 0.9724826812744141, 'what is deferred tax liabilities ?', '$22 million']",deferred tax liabilities,0.972482681274414,what is deferred tax liabilities ?,$22 million,Deferred tax liabilities
23,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.",29,"['Fair value of assets acquired and liabilities assumed, net other assets and liabilities']",amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities,monetaryItemType,amgn,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.",$29 million,MONEY,"We allocated the consideration to acquire Nuevolution to finite lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.","['intangible assets', 'technology rights for discovery platform', 'estimated useful life of years', 'goodwill', 'deferred tax liabilities', 'other net assets', 'intangible assets', 'technology rights', 'discovery platform', 'useful life']","['other net assets', 0.9693720936775208, 'what is other net assets ?', '$29 million']",other net assets,0.9693720936775208,what is other net assets ?,$29 million,Other net assets
24,"During the first quarter of 2018, we acquired the remaining 50% ownership of Kirin Amgen, Inc. (K A), from Kirin Holdings Company, Limited (Kirin), making K A a wholly owned subsidiary of Amgen. Upon the acquisition, K A's operations have been included in our consolidated financial statements commencing on the share acquisition date. The acquisition relieved Amgen of future royalty obligations to K A.",50,['Percentage of voting interests acquired'],us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired,percentItemType,amgn,"During the first quarter of 2018, we acquired the remaining 50% ownership of Kirin Amgen, Inc. (K A), from Kirin Holdings Company, Limited (Kirin), making K A a wholly owned subsidiary of Amgen.",50%,PERCENT,"During the first quarter of 2018, we acquired the remaining 50% ownership of Kirin Amgen, Inc. , from Kirin Holdings Company, Limited , making K A a wholly owned subsidiary of Amgen.","['remaining % ownership of Kirin Amgen', 'remaining % ownership from Kirin Holdings Company', 'owned subsidiary of Amgen', '% ownership']","['% ownership', 0.5652069449424744, 'what is % ownership ?', '50%']",% ownership,0.5652069449424744,what is % ownership ?,50%,"Kirin Holdings Company, Limited"
25,"Prior to the share acquisition date, we owned 50% of K A and accounted for our interest in K A by using the equity method of accounting.",50,['Ownership percentage'],us-gaap_EquityMethodInvestmentOwnershipPercentage,percentItemType,amgn,"Prior to the share acquisition date, we owned 50% of K A and accounted for our interest in K A by using the equity method of accounting.",50%,PERCENT,"Prior to the share acquisition date, we owned 50% of K A and accounted for our interest in K A by using the equity method of accounting.","['% of K A', 'interest in K A', 'equity method of accounting', 'share acquisition date', 'equity method']","['% of K A', 0.9381483197212219, 'what is % of K A ?', '50%']",% of K A,0.938148319721222,what is % of K A ?,50%,Our interest in K A
26,"The transaction was accounted for as a step acquisition of a business in which we were required to remeasure our existing 50% ownership interest at fair value. In addition, we were required to effectively settle our preexisting relationship with K A, which resulted in a loss. Together the gain on the remeasurement of our existing ownership interest and the loss from the settlement of the preexisting relationship resulted in a net gain of $80 million, which was recorded in Interest and other income, net, in the Consolidated Statements of Income.",50,['Ownership interest in acquiree prior to acquisition'],us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage,percentItemType,amgn,The transaction was accounted for as a step acquisition of a business in which we were required to remeasure our existing 50% ownership interest at fair value.,50%,PERCENT,The transaction was accounted for as a step acquisition of a business in which we were required to remeasure our existing 50% ownership interest at fair value.,"['step acquisition of business', 'step acquisition', '% ownership interest', 'fair value']","['fair value', 0.7890093326568604, 'what is fair value ?', '50% ownership interest']",fair value,0.7890093326568604,what is fair value ?,50% ownership interest,Existing ownership interest
27,"The transaction was accounted for as a step acquisition of a business in which we were required to remeasure our existing 50% ownership interest at fair value. In addition, we were required to effectively settle our preexisting relationship with K A, which resulted in a loss. Together the gain on the remeasurement of our existing ownership interest and the loss from the settlement of the preexisting relationship resulted in a net gain of $80 million, which was recorded in Interest and other income, net, in the Consolidated Statements of Income.",80,['Net gain on remeasurement'],us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss,monetaryItemType,amgn,"Together the gain on the remeasurement of our existing ownership interest and the loss from the settlement of the preexisting relationship resulted in a net gain of $80 million, which was recorded in Interest and other income, net, in the Consolidated Statements of Income.",$80 million,MONEY,"Together the gain on the remeasurement of our existing ownership interest and the loss from the settlement of the preexisting relationship resulted in a net gain of $80 million, which was recorded in Interest and other income, net, in the Consolidated Statements of Income.","['gain on remeasurement', 'remeasurement of existing ownership interest', 'loss from settlement', 'settlement of preexisting relationship', 'net gain', 'ownership interest', 'net gain']","['net gain', 0.9126874804496765, 'what is net gain ?', '$80 million']",net gain,0.9126874804496764,what is net gain ?,$80 million,net gain
28,The primary means of consideration for this transaction was a payment of $780 million in cash. The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K A and the fair value of Amgen's preacquisition investment consisted of the following (in millions):,780,"['Cash paid', 'Cash purchase price']",us-gaap_PaymentsToAcquireBusinessesGross,monetaryItemType,amgn,The primary means of consideration for this transaction was a payment of $780 million in cash.,$780 million,MONEY,The primary means of consideration for this transaction was a payment of $780 million in cash.,"['primary means of consideration', 'primary means for transaction', 'payment', 'primary means']","['cash', 0.6986864805221558, 'What is $780 million ?', 'cash']",cash,0.6986864805221558,What is $780 million ?,cash,primary means of consideration
29,The primary means of consideration for this transaction was a payment of $780 million in cash. The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K A and the fair value of Amgen's preacquisition investment consisted of the following (in millions):,50,['Percentage of voting interests acquired'],us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired,percentItemType,amgn,The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K A and the fair value of Amgen’s preacquisition investment consisted of the following (in millions):,the remaining 50%,PERCENT,The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K A and the fair value of Amgen’s preacquisition investment consisted of the following :,"['remaining % ownership in K A', 'fair value of preacquisition investment', 'date consideration', '% ownership', 'fair value', 'preacquisition investment']","['date consideration', 0.21058781445026398, 'what is date consideration ?', 'to acquire the remaining 50% ownership in K A']",date consideration,0.2105878144502639,what is date consideration ?,to acquire the remaining 50% ownership in K A,share acquisition date consideration
30,"In connection with this acquisition, we are obligated to make single digit royalty payments to Kirin contingent upon sales of brodalumab. The estimated fair value of this contingent consideration obligation was $45 million as of the share acquisition date.",45,['Estimated fair values of contingent consideration obligations'],amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions,monetaryItemType,amgn,The estimated fair value of this contingent consideration obligation was $45 million as of the share acquisition date.,$45 million,MONEY,The estimated fair value of this contingent consideration obligation was $45 million as of the share acquisition date.,"['estimated fair value of contingent consideration obligation', 'fair value', 'contingent consideration obligation', 'share acquisition date']","['estimated fair value of contingent consideration obligation', 0.983433723449707, 'what is estimated fair value of contingent consideration obligation ?', '$45 million']",estimated fair value of contingent consideration obligation,0.983433723449707,what is estimated fair value of contingent consideration obligation ?,$45 million,Contingent consideration obligation
31,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability related income approach, which is based on the present value of the incremental after tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted average period of four years by using the straight line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities primarily represents receivables for royalties earned by K A but not yet received, partially offset by payables representing R&D expenses incurred but not yet reimbursed by K A.",977,"['Fair value of assets acquired, cash']",us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents,monetaryItemType,amgn,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.",$977 million,MONEY,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.","['fair values of assets', 'cash', 'licensing rights', 'tax liabilities', 'other assets', 'fair values', 'licensing rights', 'tax liabilities']","['cash', 0.9911763668060303, 'What is $977 million ?', 'cash']",cash,0.9911763668060304,What is $977 million ?,cash,"Cash

Entity: 
$470 million
Phrase: 
Licensing rights"
32,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability related income approach, which is based on the present value of the incremental after tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted average period of four years by using the straight line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities primarily represents receivables for royalties earned by K A but not yet received, partially offset by payables representing R&D expenses incurred but not yet reimbursed by K A.",470,"['Fair value of assets acquired, licensing rights']",us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles,monetaryItemType,amgn,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.",$470 million,MONEY,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.","['fair values of assets', 'cash', 'licensing rights', 'tax liabilities', 'other assets', 'fair values', 'licensing rights', 'tax liabilities']","['licensing rights', 0.9960182905197144, 'What is $470 million ?', 'licensing rights']",licensing rights,0.9960182905197144,What is $470 million ?,licensing rights,licensing rights
33,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability related income approach, which is based on the present value of the incremental after tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted average period of four years by using the straight line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities primarily represents receivables for royalties earned by K A but not yet received, partially offset by payables representing R&D expenses incurred but not yet reimbursed by K A.",102,"['Fair value of liabilities assumed, deferred tax liabilities']",us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities,monetaryItemType,amgn,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.",$102 million,MONEY,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.","['fair values of assets', 'cash', 'licensing rights', 'tax liabilities', 'other assets', 'fair values', 'licensing rights', 'tax liabilities']","['tax liabilities', 0.9527063369750977, 'what is tax liabilities ?', '$102 million']",tax liabilities,0.9527063369750975,what is tax liabilities ?,$102 million,Deferred tax liabilities
34,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability related income approach, which is based on the present value of the incremental after tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted average period of four years by using the straight line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities primarily represents receivables for royalties earned by K A but not yet received, partially offset by payables representing R&D expenses incurred but not yet reimbursed by K A.",131,"['Fair value of assets acquired and liabilities assumed, net other assets and liabilities']",amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities,monetaryItemType,amgn,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.",$131 million,MONEY,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.","['fair values of assets', 'cash', 'licensing rights', 'tax liabilities', 'other assets', 'fair values', 'licensing rights', 'tax liabilities']","['liabilities', 0.8829450011253357, 'What is $131 million ?', 'liabilities']",liabilities,0.8829450011253357,What is $131 million ?,liabilities,Other assets and liabilities
35,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability related income approach, which is based on the present value of the incremental after tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted average period of four years by using the straight line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities primarily represents receivables for royalties earned by K A but not yet received, partially offset by payables representing R&D expenses incurred but not yet reimbursed by K A.",6,"['Goodwill', 'Goodwill']",us-gaap_Goodwill,monetaryItemType,amgn,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.",$6 million,MONEY,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.","['fair values of assets', 'cash', 'licensing rights', 'tax liabilities', 'other assets', 'fair values', 'licensing rights', 'tax liabilities']","['goodwill', 0.9984645247459412, 'What is $6 million ?', 'goodwill']",goodwill,0.9984645247459412,What is $6 million ?,goodwill,goodwill
36,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability related income approach, which is based on the present value of the incremental after tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted average period of four years by using the straight line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities primarily represents receivables for royalties earned by K A but not yet received, partially offset by payables representing R&D expenses incurred but not yet reimbursed by K A.",four years,['Weighted average period of amortization'],us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife,durationItemType,amgn,The licensing rights will be amortized over a weighted average period of four years by using the straight line method.,four years,DATE,The licensing rights will be amortized over a weighted average period of four years by using the straight line method.,"['weighted average period of years', 'licensing rights', 'weighted average period', 'straight line method']","['weighted average period', 0.9519851803779602, 'what is weighted average period ?', 'four years']",weighted average period,0.9519851803779602,what is weighted average period ?,four years,The licensing rights will be amortized over a weighted average period by using the straight line method.
37,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability related income approach, which is based on the present value of the incremental after tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted average period of four years by using the straight line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities primarily represents receivables for royalties earned by K A but not yet received, partially offset by payables representing R&D expenses incurred but not yet reimbursed by K A.",6,"['Goodwill', 'Goodwill']",us-gaap_Goodwill,monetaryItemType,amgn,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.",$6 million,MONEY,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.","['fair values of assets', 'cash', 'licensing rights', 'tax liabilities', 'other assets', 'fair values', 'licensing rights', 'tax liabilities']","['goodwill', 0.9984645247459412, 'What is $6 million ?', 'goodwill']",goodwill,0.9984645247459412,What is $6 million ?,goodwill,Goodwill
38,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability related income approach, which is based on the present value of the incremental after tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted average period of four years by using the straight line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities primarily represents receivables for royalties earned by K A but not yet received, partially offset by payables representing R&D expenses incurred but not yet reimbursed by K A.",131,"['Fair value of assets acquired and liabilities assumed, net other assets and liabilities']",amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities,monetaryItemType,amgn,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.",$131 million,MONEY,"The fair values of assets acquired and liabilities assumed consisted of cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million.","['fair values of assets', 'cash', 'licensing rights', 'tax liabilities', 'other assets', 'fair values', 'licensing rights', 'tax liabilities']","['liabilities', 0.8829450011253357, 'What is $131 million ?', 'liabilities']",liabilities,0.8829450011253357,What is $131 million ?,liabilities,Other assets and liabilities
39,"We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers' locations, are presented below. The majority of rest of world (ROW) revenues relates to products sold in Europe.",one,"['Number of operating segments', 'Number of business segment']",us-gaap_NumberOfOperatingSegments,integerItemType,amgn,We operate in one business segment: human therapeutics.,one,CARDINAL,We operate in one business segment: human therapeutics.,['business segment'],"['human therapeutics', 0.9611589312553406, 'What is one ?', 'human therapeutics']",human therapeutics,0.9611589312553406,What is one ?,human therapeutics,business segment
40,"We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018. For the year ended December 31, 2020, on a combined basis, these customers accounted for 83% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):",three,['Number of major customers  accounting for more than 10% of total revenue'],amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue,integerItemType,amgn,"We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018.",three,CARDINAL,"We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018.","['% of total revenues', 'product sales', 'total revenues']","['product sales', 0.7709255814552307, 'how many product sales ?', 'three']",product sales,0.7709255814552307,how many product sales ?,three,product sales
41,"We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018. For the year ended December 31, 2020, on a combined basis, these customers accounted for 83% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):",three,['Number of major customers  accounting for more than 10% of total revenue'],amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue,integerItemType,amgn,"We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018.",three,CARDINAL,"We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018.","['% of total revenues', 'product sales', 'total revenues']","['product sales', 0.7709255814552307, 'how many product sales ?', 'three']",product sales,0.7709255814552307,how many product sales ?,three,total revenue customers
42,"We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018. For the year ended December 31, 2020, on a combined basis, these customers accounted for 83% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):",three,['Number of major customers  accounting for more than 10% of total revenue'],amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue,integerItemType,amgn,"We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018.",three,CARDINAL,"We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018.","['% of total revenues', 'product sales', 'total revenues']","['product sales', 0.7709255814552307, 'how many product sales ?', 'three']",product sales,0.7709255814552307,how many product sales ?,three,product sales
43,"We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018. For the year ended December 31, 2020, on a combined basis, these customers accounted for 83% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):",83,['Percentage of worldwide gross revenues derived from major customers  on a combined basis'],amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers,percentItemType,amgn,"For the year ended December 31, 2020, on a combined basis, these customers accounted for 83% of total gross revenues as shown in the following table.",83%,PERCENT,"For the year ended December 31, 2020, on a combined basis, these customers accounted for 83% of total gross revenues as shown in the following table.","['% of total gross revenues', 'combined basis', 'total gross revenues']","['total gross revenues', 0.9905943274497986, 'what is total gross revenues ?', '83%']",total gross revenues,0.9905943274497986,what is total gross revenues ?,83%,Total gross revenues
44,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2020 and 2019, was not material.",three,['Major customers  accounting for more than 10% of gross trade receivables'],amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables,integerItemType,amgn,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis.",three,CARDINAL,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis.","['% of trade receivables', 'net trade receivables on combined basis', 'trade receivables', 'net trade receivables', 'combined basis']","['', 0, '', '']",,0.0,,,net trade receivables
45,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2020 and 2019, was not material.",three,['Major customers  accounting for more than 10% of gross trade receivables'],amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables,integerItemType,amgn,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis.",three,CARDINAL,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis.","['% of trade receivables', 'net trade receivables on combined basis', 'trade receivables', 'net trade receivables', 'combined basis']","['', 0, '', '']",,0.0,,,gross trade receivables
46,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2020 and 2019, was not material.",74,['Combined trade receivables for all major customers  as a percentage of net trade receivables'],amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers,percentItemType,amgn,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis.",74% and 73%,PERCENT,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis.","['% of trade receivables', 'net trade receivables on combined basis', 'trade receivables', 'net trade receivables', 'combined basis']","['net trade receivables', 0.8583109974861145, 'What is 74% and 73% ?', 'net trade receivables']",net trade receivables,0.8583109974861145,What is 74% and 73% ?,net trade receivables,Net trade receivables
47,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2020 and 2019, was not material.",73,['Combined trade receivables for all major customers  as a percentage of net trade receivables'],amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers,percentItemType,amgn,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis.",74% and 73%,PERCENT,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis.","['% of trade receivables', 'net trade receivables on combined basis', 'trade receivables', 'net trade receivables', 'combined basis']","['net trade receivables', 0.8583109974861145, 'What is 74% and 73% ?', 'net trade receivables']",net trade receivables,0.8583109974861145,What is 74% and 73% ?,net trade receivables,gross trade receivables and net trade receivables
48,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2020 and 2019, was not material.",28,"['Percentage of net trade receivables due from customers located outside the United States, primarily in Europe']",amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation,percentItemType,amgn,"As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe.",28% and 27%,PERCENT,"As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe.","['majority', 'net trade receivables']","['net trade receivables', 0.7924699187278748, 'What is 28% and 27% ?', 'net trade receivables']",net trade receivables,0.7924699187278748,What is 28% and 27% ?,net trade receivables,Net trade receivables
49,"As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2020 and 2019, was not material.",27,"['Percentage of net trade receivables due from customers located outside the United States, primarily in Europe']",amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation,percentItemType,amgn,"As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe.",28% and 27%,PERCENT,"As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe.","['majority', 'net trade receivables']","['net trade receivables', 0.7924699187278748, 'What is 28% and 27% ?', 'net trade receivables']",net trade receivables,0.7924699187278748,What is 28% and 27% ?,net trade receivables,Net trade receivables
